Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eli Lilly & Co. (LLY) Tops Q3 EPS by 2c; Reviewing Strategic Alternatives for Elanco Animal Health
October 24, 2017 6:28 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.05, $0.02 better than the analyst estimate of $1.03. Revenue for the quarter came in at $5.66 billion versus the consensus estimate of $5.52 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2017 EPS of $4.15-$4.25, versus the... More
